Fuiou may enjoy policy tailwind on ride to Hong Kong IPO
The payment services provider looks well-positioned to benefit from China’s consumption-boosting policies as it seeks to list Key Takeaways: Hong Kong IPO candidate Fuiou could get a lift from China’s…
Zhipu in race to become first to list among new generation of Chinese ‘AI tigers’
The company, which focuses on large language models for enterprise clients, has raised 2 billion yuan this year, from mostly government sources Key Takeaways: Zhipu AI is aiming to become…
Busy Ming buzzes investors with China’s love of budget snacks
The snack store operator has filed for a Hong Kong IPO, using steep cost controls to offer up cheap eats in less affluent smaller cities Key Takeaways: Busy Ming has…
Keytop seeks to turn China’s parking pain into opportunity
The provider of smart parking technologies wants to capitalize on a shortage of spaces in Chinese cities as it looks to go public in Hong Kong Key Takeaways: Keytop has…
Three Squirrels chases Hong Kong listing in scurry for offshore cash
The snack food maker is joining a wave of companies listed on China’s domestic A-share markets hoping to target global investors with second IPOs in Hong Kong Key Takeaways: China’s…
Janbon makes contrarian IPO application into solar storm
The maker of a key component for solar cells remained profitable last year, even as many of the industry’s more downstream players sank into the red Key Takeaways: Janbon High…
Novosense eyes Hong Kong IPO as competition chips away at its cash
The analog chipmaker’s cash and margins dropped sharply last year, sending it into the red Key Takeaways: Novosense has filed for a Hong Kong IPO, posting strong revenue growth last…
Recent Articles
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
